Vnitr Lek 2007, 53(4):396-400

Secondary dyslipidemias and their treatment

V. Soška
Oddělení klinické biochemie FN u sv. Anny Brno, přednosta doc. MUDr. Vladimír Soška, CSc.

Secondary dyslipidemias may develop as a result of other diseases or some major exogenous influences. The most common are secondary dyslipidemias due to the following diseases: poorly controlled diabetes mellitus, hypothyreosis, hyperfunction of suprarenal glands, cholestasis, chronic renal diseases (chronic renal failure, nephrotic syndrome), acute infectious diseases. A very common cause of secondary dyslipidemia is abuse of alcohol. Also some drugs may induce dyslipidemias: corticosteroids, immunosuppressive drugs, less frequently also thiazide diuretics and non-selective beta-blockers. Secondary dyslipidemia is physiologic during pregnancy. If causal treatment of secondary dyslipidemia is possible, hypolipidemic drugs are not indicated. The decision to initiate treatment with hypolipidemic drugs depends on the degree of risk of a fatal cardiovascular event rather than on the blood lipids level. When hypolipidemic treatment is indicated, the choice of the drug and its dose also depends on the type of the primary disease and its severity.

Keywords: secondary dyslipidemia; diabetes mellitus; hypothyreosis; steatosis hepatis; chronic renal failure; immunosuppressive drugs; alcohol

Received: March 29, 2007; Published: April 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soška V. Secondary dyslipidemias and their treatment. Vnitr Lek. 2007;53(4):396-400.
Download citation

References

  1. Soška V. Familiární hypercholesterolemie: Dovedeme ji správně diagnostikovat? Vnitř Lék 2000; 46: 19-23. Go to PubMed...
  2. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628. Go to original source...
  3. Soška V. Dyslipidemie u metabolického syndromu. Vnitř Lék 2005; 51: 77-81.
  4. Manzato E, Zambon A, Lapolla A et al. Lipoprotein abnormalities in well-treated type II diabetic patients. Diabetes Care 1993; 16: 469-475. Go to original source... Go to PubMed...
  5. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181-197. Go to PubMed...
  6. Salter AM, Hayashi R, Al-Seeni M et al. Effects of hypothyreoidism and high-fat feedeng on mRNA concentration for the low-density-lipoprotein receptors and on acyl-CoA: cholesterol acyltransferaze activities in rat liver. Biochem J 1991; 276: 825-832. Go to original source... Go to PubMed...
  7. Olšovská V, Šiprová H, Beránek M et al. Vliv dlouhodobé substituční terapie růstovým hormonem na tělesné složení, kostní tkáň a některé metabolické parametry u dospělých osob s deficitem růstového hormonu. Vnitř Lék 2005; 51: 1356-1364. Go to PubMed...
  8. DeBoer H, Blok G, Voerman H et al. A lipid levels in growth hormon-deficient men. Metabolism 1994; 43: 199-203. Go to original source... Go to PubMed...
  9. Miller JP. Liver disease. In: Betteridge DJ, Illingworth DR. Lipoproteins in health and disease. London: Arnold 1999: 985-1009.
  10. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006; 29: 1845-1850. Go to original source... Go to PubMed...
  11. Soška V. Hyperlipoproteinaemia in chronic renal failure: Aethiology and therapy. Klin Biochem Metab 1994; 3: 116-118.
  12. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006; 26: 523-539. Go to original source... Go to PubMed...
  13. Szromba C. Dyslipidemias in chronic kidney disease. Nephrol Nurs J 2006; 33: 575-576. Go to PubMed...
  14. Kimak E, Solski J, Baranowicz-Gaszczyk I et al. A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients. Ren Fail 2006; 28: 483-486. Go to original source... Go to PubMed...
  15. Black H. Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J 1992; 121: 707-715. Go to original source... Go to PubMed...
  16. Stampfer M, Willett W, Colditz G et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319: 1311-1317. Go to original source... Go to PubMed...
  17. Knopp RH. Cardiovascular effects of endogenous and exogenous sex hormones over a woman's lifetime. Am J Obstetrics Gynekol 1988; 158: 1630-1643. Go to original source... Go to PubMed...
  18. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. Arch Intern Med 1991; 151: 1925-1933. Go to original source...
  19. Crouse JR, Grundy SM. Effects of alcohol on plasma lipoproteins and cholesterol and triglyceride metabolism in man. J Lipid Res 1984; 25: 1721-1724. Go to original source...
  20. Baraona E, Lieber CS. Alcohol. In: Betteridge DJ, Illingworth DR. Lipoproteins in health and disease. London: Arnold 1999: 1011-1036.
  21. Gallin JI, Kaye D, O'Leary WM. Serum lipids in infection. N Engl J Med 1969; 281: 1081-1086. Go to original source... Go to PubMed...
  22. Soška V. Poruchy metabolizmu lipidů. Diagnostika a léčba. 1. vyd. Praha: Grada Publishing 2001.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.